Turtle Cameron
SEC insider (Form 3/4/5 filer). CIK 0001758363. Chief Executive Officer at Spyre Therapeutics, Inc. (SYRE) and 2 other issuers. 44 reported Form 4/5 transactions since Sep 2024; latest on Oct 1, 2026. Located in WALTHAM, MA.
Companies Turtle Cameron has filed insider reports for
- Spyre Therapeutics, Inc. (SYRE): Director, Officer, Chief Executive Officer
- Damora Therapeutics, Inc. (DMRA): Director
- Oruka Therapeutics, Inc. (ORKA): Director
Turtle Cameron
CIK: 0001758363
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (44 total)
- Oct 1, 2026SYRE
Spyre Therapeutics, Inc.
SaleDirect4K shares at avg. $92.31$368K - Oct 1, 2026SYRE
Spyre Therapeutics, Inc.
SaleDirect600 shares at avg. $89.14$53K - Oct 1, 2026SYRE
Spyre Therapeutics, Inc.
SaleDirect5K shares at avg. $93.37$466K - Oct 1, 2026SYRE
Spyre Therapeutics, Inc.
SaleDirect2.7K shares at avg. $90.10$242K - Oct 1, 2026SYRE
Spyre Therapeutics, Inc.
SaleDirect100 shares at avg. $93.91$9K - Oct 1, 2026SYRE
Spyre Therapeutics, Inc.
SaleDirect2.6K shares at avg. $91.49$241K - Sep 1, 2026SYRE
Spyre Therapeutics, Inc.
SaleDirect8.4K shares at avg. $87.15$732K - Sep 1, 2026SYRE
Spyre Therapeutics, Inc.
SaleDirect2.5K shares at avg. $86.36$216K - Sep 1, 2026SYRE
Spyre Therapeutics, Inc.
SaleDirect3.7K shares at avg. $88.06$326K - Sep 1, 2026SYRE
Spyre Therapeutics, Inc.
SaleDirect400 shares at avg. $89.07$36K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 1, 2026 |  SYRE Spyre Therapeutics, Inc. | Sale | 3,989 | $92.31 | $368,225 | Direct |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 600 | $89.14 | $53,484 | Direct |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 4,990 | $93.37 | $465,916 | Direct |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 2,683 | $90.10 | $241,738 | Direct |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 100 | $93.91 | $9,391 | Direct |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 2,638 | $91.49 | $241,351 | Direct |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 8,400 | $87.15 | $732,060 | Direct |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 2,500 | $86.36 | $215,900 | Direct |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 3,700 | $88.06 | $325,822 | Direct |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 400 | $89.07 | $35,628 | Direct |
1-10 of 44 transactions